Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
JERSEY, Channel Islands, Nov. 15, 2016 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company’s Chairman and Chief Executive Officer, Paul Cowan, will present at the Jefferies 2016 London Healthcare Conference in London, UK on Thursday, November 17 at 4.00 p.m. GMT (11.00 a.m. Eastern Time).
A live audio webcast of the presentation will be available online from the investor relations page of the Company’s corporate website at www.quotientbd.com. A webcast replay will be archived on the website for approximately 45 days.
About Quotient Limited
Quotient is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative tests within established markets. With an initial focus on blood grouping and serological disease screening, Quotient is developing its proprietary MosaiQTM technology platform to offer a breadth of tests that is unmatched by existing commercially available transfusion diagnostic instrument platforms. The company’s operations are based in Edinburgh, Scotland; Eysins, Switzerland and Newtown, Pennsylvania.
Contact: Paul Cowan, Chairman & Chief Executive Officer – [email protected]; 215-497-7006
